Global Big Pharma Partnering Terms and Agreements 2014 to 2021 report provides a detailed understanding and analysis of how and why companies enter Big Pharma partnering deals.
These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.
This report provides details of the latest Big Pharma agreements announced in the life sciences since 2014.
The report takes the reader through a comprehensive review Big Pharma deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Big Pharma partnering deals.
The report presents financial deal term values for Big Pharma deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.
The middle section of the report explores the leading dealmakers in the Big Pharma partnering field; both the leading deal values and most active Big Pharma dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.
One of the key highlights of the report is that over 3,900 online deal records of actual Big Pharma deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.
In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
The initial chapters of this report provide an orientation of Big Pharma dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Big Pharma dealmaking since 2014, including details of headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading Big Pharma deals since 2014. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 50 most active companies including Pfizer, Sanofi, Abbott, GlaxoSmithKline, Johnson & Johnson and many others, in Big Pharma dealmaking with a brief summary followed by a comprehensive listing of Big Pharma deals announded by that company, as well as contract documents, where available.
Chapter 5 provides a comprehensive and detailed review of Big Pharma partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of Big Pharma partnering deals signed and announced since Jan 2014. The chapter is organized by specific technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
A comprehensive series of appendices is provided organized by Big Pharma partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Big Pharma partnering and dealmaking since 2014.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Big Pharma technologies and products.
Key benefits Global Big Pharma Partnering Terms and Agreements 2014-2021 provides the reader with the following key benefits: In-depth understanding of Big Pharma deal trends since 2014 Access to headline, upfront, milestone and royalty data Detailed access to actual Big Pharma contracts entered into by leading biopharma companies Identify most active Big Pharma dealmakers since 2014 Understand the key deal terms companies have agreed in previous deals Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Report scope Global Big Pharma Partnering Terms and Agreements 2014-2021 is intended to provide the reader with an in-depth understanding and access to Big Pharma trends and structure of deals entered into by leading companies worldwide.
Big Pharma Partnering Terms and Agreements includes: Trends in Big Pharma dealmaking in the biopharma industry since 2014 Access to headline, upfront, milestone and royalty data Access to Big Pharma contract documents Leading Big Pharma deals by value since 2014 Most active Big Pharma dealmakers since 2014
In Global Big Pharma Partnering Terms and Agreements 2014-2021, the available deals are listed by: Company A-Z Headline value Stage of development at signing Deal component type Specific therapy target Technology type
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Big Pharma Partnering Terms and Agreements 2014-2021s report provides comprehensive access to available deals and contract documents for over 3,900 Big Pharma deals.
Analyzing actual contract agreements allows assessment of the following: • What are the precise rights granted or optioned? • What is actually granted by the agreement to the partner company? • What exclusivity is granted? • What is the payment structure for the deal? • How are sales and payments audited? • What is the deal term? • How are the key terms of the agreement defined? • How are IPRs handled and owned? • Who is responsible for commercialization? • Who is responsible for development, supply, and manufacture? • How is confidentiality and publication managed? • How are disputes to be resolved? • Under what conditions can the deal be terminated? • What happens when there is a change of ownership? • What sublicensing and subcontracting provisions have been agreed? • Which boilerplate clauses does the company insist upon? • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? • Which jurisdiction does the company insist upon for agreement law?
Our reports have been used by over 10K customers, including:
The Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading biopharma companies. This report provides...
The global cosmeceuticals market exhibited moderate growth during 2015-2020. Looking forward, the analyst expects the market to grow at a CAGR of around 5% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the...
175 pages •
By The Business Research Company
• Sep 2021
Major players in the desiccants market are Porocel, The Dow Chemical, INEOS, Fuji Silysia Chemical, and Hengye Molecular Sieve. The global desiccants market is expected to grow from $0.13 billion in 2020 to $0.14 billion in 2021 at a compound annual growth rate (CAGR) of 7.7%. The growth is mainly due to the companies resuming their...
Report Scope: This report provides a detailed description of flexible manufacturing systems in the pharmaceutical industry and the latest technologies in the market. The report includes market estimates for different types of flexible manufacturing systems and also includes recent technological developments and assessments...
Pharmaceutical Analytical Testing market is one of the high-growth prospect industries with potential opportunities throughout 2028. The Pharmaceutical Analytical Testing Market growth analysis and insights report analyzes emerging market trends, market size outlook, potential opportunities, market share by Pharmaceutical Analytical Testing...
Global Specialty Pharmaceutical Partnering Terms and Agreements 2014 to 2021 report provides a detailed understanding and analysis of how and why companies enter Specialty Pharmaceutical partnering deals. This report provides details of the latest Specialty Pharmaceutical agreements announced in the life sciences since...
Retinoic Acid Receptor Gamma - Drugs In Development, 2021 Summary Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Retinoic acid receptor gamma (RARG) is a nuclear receptor that is encoded by the RARG gene. RARG bind as heterodimers to the...
The pharmaceutical isolator market was valued at 5,966.07 million in 2021 and is projected to reach US$ 10,560.30 million by 2028; it is expected to grow at a CAGR of 8.5 % from 2021 to 2028. The growth of the pharmaceutical isolator market is attributed to factors such as an increase in investments by the pharmaceutical and biotechnology...
The analyst presents post-COVID-19 growth opportunities and strategic imperatives for the global drug discovery and early development outsourcing market in this study, which covers research and development (R&D) efforts, market trends, key participants, drivers and restraints of market adoption, and recent mergers and acquisitions. The report...
The thermal pallet covers market was valued at US$ 4,599.65 million in 2021 and is projected to reach US$ 10,469.73 million by 2028; it is expected to grow at a CAGR of 12.5% from 2021 to 2028. Thermal pallet covers safeguard temperature-sensitive goods from the effects of harsh weather and decrease the risk of excursions.The heat transmission...
Final Consumption Expenditures
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.